EUS-guided radiofrequency ablation for pancreatic insulinoma safety and effectiveness

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

EUS-guided radiofrequency ablation (EUS-RFA) is offered to patients referred to Sahlgrenska University Hospital with suspected and pathology-confirmed pancreatic insulinoma. This observational, single-center project will record technical feasibility, patient safety, and clinical efficacy of EUS-RFA and compare outcomes to historic surgical controls treated from 2018–2025. Clinical follow-up includes biochemical testing and imaging at 3, 6, 12, and 24 months to monitor glucose control, tumor response, and complications. Eligible patients typically have insulinoma confirmed by pathology (often from EUS-FNB) and are able to provide informed consent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Insulinoma verified by pathology (often from EUS-FNB-sampling)

Exclusion Criteria:

* Patients unwilling to participate
* Patients unable to understand and obtain written informed conscent
* Severe comorbidity

Where it's running

• Sahlgrenska Univeristy Hospital
  Gothenburg, Sweden Recruiting

Study contacts

• Study coordinator: Per Hedenström, Associate Professor
• Email: per.hedenstrom@vgregion.se
• Phone: +46 31 3421000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endoscopic ultrasound-guided radiofrequency ablation for pancreatic and left adrenal lesions

  This will try EUS-guided radiofrequency ablation to control symptoms and hormone-related problems in adults with small pancreatic neuroendocrine tumors (including insulinomas) or certain left adrenal adenomas.

  Recruiting Herlev Hospital · Herlev, Capital Region · NCT07272187

• A new PET/CT test to find insulinoma using a GLP-1R tracer compared to an earlier tracer

  A GLP-1 receptor–targeted PET/CT imaging agent is being tested in adults with suspected or confirmed insulinoma to see if the PEG6-modified tracer locates tumors better than the original tracer.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07808879

• Assessing pancreas changes during pregnancy

  This study is testing how the size of the pancreas changes during pregnancy in women and their babies, especially looking at the effects of diabetes.

  Recruiting University of Texas at Austin · Austin, Texas · NCT06784674

• Evaluating pancreatic fistula rates after surgery using a specific stapler

  This study is testing if using a specific stapler during pancreas surgery can lower the chances of complications like pancreatic fistulas in patients.

  Recruiting University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg · NCT06764134

• Using PET/CT imaging to diagnose GLP-1 receptor related diseases

  This study is testing a special imaging scan to see if it can help doctors better diagnose cancer in adults who may have diseases related to GLP-1 receptors.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06725693

• Evaluating the ERAS program's impact on recovery after pancreatic surgery

  This study is testing if following a special recovery program can help people recover better after pancreatic surgery.

  Recruiting University of Thessaly · Larissa · NCT05518643

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.